Investigation announced for NASDAQ: SCPH investors over potential Violations of Securities Laws by scPharmaceuticals Inc.

An investigation was announced concerning possible securities laws violations by scPharmaceuticals Inc. and certain of its directors and officers in connection with certain financial statements.

Investors who purchased shares of scPharmaceuticals Inc. (NASDAQ: SCPH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of scPharmaceuticals Inc. (NASDAQ: SCPH) concerning whether a series of statements by scPharmaceuticals Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Burlington, MA based scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. scPharmaceuticals Inc. went public in November 2017 and sold 6,400,000 shares of common stock at a public offering price of $14.00 per share, for gross proceeds of $89.6 million.

On December 7, 2020, scPharmaceuticals announced the receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") on December 3, 2020 regarding the Company's New Drug Application ("NDA") for the Company's FUROSCIX product. scPharmaceuticals Inc’s announcement stated that "[i]n the CRL, the FDA cited their need to conduct pre-approval inspections at two of the company's third-party manufacturing facilities that could not be conducted due to travel restrictions. In addition, the FDA raised questions related to testing, labeling, and features of the combination product unrelated to the drug constituent. In addition, the FDA indicated that there were deficiencies at the third-party facility where the Company's off-the-shelf alcohol swabs are manufactured."

Shares of scPharmaceuticals Inc. (NASDAQ: SCPH) declined on December 8, 2020, to $5.09 per share.

Those who purchased shares of scPharmaceuticals Inc. (NASDAQ: SCPH) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.